Trial Profile
Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irofulven (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 06 Nov 2008 'Eisai Medical Research' added as trial sponsor as reported by ClinicalTrials.gov.
- 27 Jan 2007 Status changed from recruiting to completed
- 13 Nov 2005 New trial record.